

*Cervista*<sup>TM</sup> HPV HR

**Cervista<sup>®</sup> HPV HR**


**REF 92-011, PRD-01560**

**INTENDED USE**

The Cervista<sup>®</sup> HPV HR test is intended for two uses:

- 1) In combination with cervical cytology screening for women age 30 and above to guide patient management.
- 2) To triage patients with atypical squamous cells of undetermined significance (ASC-US) Pap test results to determine the need for referral to colposcopy.

**IVD**

92-011- 

-30°C  -15°C

PRD-01560- 



**EC REP**

Hologic UK Ltd.  
Link 10, Napier Way,  
Crawley, West Sussex  
RH10 9RA UK  
+44 (0) 1293 522080

**Do not store in a frost-free freezer.**

**Protect from light.**

**FOR EXPORT ONLY. NOT FOR SALE IN THE UNITED STATES OF AMERICA OR CANADA.**

**TABLE OF CONTENTS**

ABBREVIATIONS USED  
HARMONIZED SYMBOLS USED  
SUMMARY AND EXPLANATION OF THE TEST  
PRINCIPLES OF THE PROCEDURE  
REAGENTS PROVIDED  
WARNINGS AND PRECAUTIONS  
STORAGE AND HANDLING REQUIREMENTS  
ADDITIONAL REAGENTS AND MATERIALS  
MATERIALS REQUIRED, BUT NOT PROVIDED

SPECIMEN COLLECTION, DNA EXTRACTION, AND STORAGE FOR ANALYSIS  
TEST PROCEDURE  
PROCEDURAL NOTES  
INTERPRETATION OF RESULTS  
QUALITY CONTROL  
LIMITATIONS  
PERFORMANCE CHARACTERISTICS  
REFERENCES  
TROUBLESHOOTING GUIDE

## **ABBREVIATIONS USED**

ASC-US:	Atypical squamous cells of undetermined significance
CIN:	Cervical intra-epithelial neoplasia
DNA:	Deoxyribonucleic acid
FAM:	Carboxyfluorescein dye
FRET:	Fluorescence resonance energy transfer
FOZ:	Fold over zero (sample or control signal divided by No Target Control signal)
gDNA:	Genomic DNA
HIST2H2BE:	Human histone 2 gene, H2be gene
HPV:	Human papillomavirus
HR:	High-risk
Max:	Maximum
Min:	Minimum
MTA	Medium Throughput Automation
NTC:	No Target Control
Oligo:	Oligonucleotide
Pap:	Papanicolaou cervical cytology test
Red:	Redmond red dye
RFU:	Relative Fluorescence Unit

## **SUMMARY AND EXPLANATION OF THE TEST**

Approximately 11,000 new U.S. cases of invasive cervical cancer and over 3,500 deaths are projected annually.<sup>1</sup> For the earliest stage of cervical cancer, the 5-year relative survival rate is 92%, and for all stages of cervical cancer, the 5-year survival rate is about 72%.<sup>1</sup> Cervical cancer is caused by persistent infection with human papillomavirus (HPV).<sup>2</sup> Cervical cancer has previously been shown to be highly preventable when cytological and HPV screening programs are employed to facilitate the detection and treatment of pre-cancerous lesions.

Over 100 HPV types have been documented in the literature, approximately 40 of which infect the anogenital area and are transmitted sexually. Of the sexually transmitted types of HPV, 14 oncogenic genotypes (HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68), referred to as high-risk (HR) types, are now recognized as the cause of almost all cervical cancers.<sup>1,2</sup> The presence of high-risk HPV DNA in conjunction with an equivocal or ambiguous cytology result (ASC-US) places a woman at increased risk for having an underlying cervical intraepithelial neoplasia 2 or 3 (CIN 2 or CIN 3).<sup>4,6,7</sup> CIN 3, while occurring in only approximately 5% of ASC-US cases,<sup>5</sup> is an immediate precursor to cervical cancer and consequently its detection is very important for patient management.<sup>2</sup> Therefore, the identification of those women with ASC-US cytology in conjunction with a high-risk HPV infection is a useful aid for clinicians to decide who should be monitored or treated more aggressively.<sup>2,4,8,9</sup>

Beginning in 2002, patient management guidelines have been published by various groups of U.S. healthcare professionals that recommend how women should be screened for cervical cancer according to age, the presence of cytological abnormalities in a Pap test sample, and other factors.<sup>6,10,11</sup> These patient management guidelines recommend testing for the presence of high-risk types of HPV as a regular screening tool, in combination with cytology, in specific instances. Principal recommendations of the most recent professional practice guidelines, the *2006 Consensus Guidelines for the Management of Women with Abnormal Cervical Cancer Screening Tests*, include: 1) screening women 30 years of age and over in conjunction with cytology or other screening methods; and 2) management of women over age 20 with ASC-US.<sup>3,11</sup> In all cases, patient management decisions reflect patients' overall cytology history and other risk factors in addition to the presence or absence of high-risk HPV types.<sup>6,8,11</sup>

## **PRINCIPLES OF THE PROCEDURE**

Cervista® HPV HR is a qualitative, *in vitro* diagnostic test for the detection of DNA from 14 high-risk HPV types, namely, types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68.


The Cervista® HPV HR test uses the Invader® chemistry, a signal amplification method for detection of specific nucleic acid sequences. This method uses two types of isothermal reactions: a primary reaction that occurs on the targeted DNA sequence and a secondary reaction that produces a fluorescent signal (See Figure 1). In the primary reaction, two types of sequence specific oligonucleotides (i.e. a probe oligonucleotide and an Invader® oligonucleotide) bind to the DNA target sequence. When these oligonucleotides overlap by at least one base pair on the target sequence, an invasive structure forms that acts as a substrate for the Cleavase® enzyme. The enzyme cleaves the 5' portion (flap) of the probe at the position of the overlap.

The probes are present in large molar excess and cycle rapidly on and off the target sequence so that many cleaved 5' flaps are generated per target sequence. The cleaved flaps then bind to a universal hairpin fluorescence resonance energy transfer (FRET) oligonucleotide creating another invasive structure that the Cleavase® enzyme recognizes as a substrate. The enzyme cleaves the FRET oligonucleotides between the fluorophore and quencher molecule and produces fluorescence signal as the cleaved flaps cycle on and off. For each copy of target, the combined primary and secondary reactions result in  $10^6$  –  $10^7$  fold signal amplification per hour<sup>12</sup>. The flap sequences and FRET oligonucleotides are universal since they are not complementary to the targeted sequence.


The reagents for this assay are provided as three oligonucleotide mixtures, which detect the 14 types of HPV grouped according to phylogenetic relatedness, i.e. viral types with similar DNA sequences. Oligonucleotides that bind to the human histone 2 gene (H2be, HIST2H2BE) are also present in these three oligonucleotide mixtures. HIST2H2BE serves as an internal control producing a semi-quantitative signal from genomic DNA present in the sample. The format of the Cervista® HPV HR test allows simultaneous detection of HPV DNA sequences and HIST2H2BE in a single well by utilizing two different 5'-flap sequences on the probes as well as two different FRET oligonucleotides, each with a spectrally distinct fluorophore (FAM and Red). By design, the released 5'-flaps bind only to their respective FRET oligonucleotides to generate target-specific signal (see Figure 1).

A positive result indicates that at least one of the 14 high-risk types is present in the DNA sample. This result is represented by a FAM fluorescent signal that lies above an empirically derived cut-off value. For each reaction, a negative result is represented by a FAM fluorescent signal that lies below an empirically derived cut-off value. As a means to determine the relative quantity of sample DNA in each reaction, Human HIST2H2BE is measured by a Red fluorescent signal that lies above an empirically derived cut-off value in each reaction. The measure of this target serves as a quality control mechanism to confirm that a negative result is not due to insufficient sample.



1a. HPV oligos form invasive structure on HPV DNA.



1b. HIST2H2BE oligos form invasive structure on genomic DNA.



2. Cleavase® enzyme recognizes structure and cleaves probe oligos





3a. Flaps from HPV probe oligos form invasive structure on FAM FRET oligos



3b. Flaps from HIST2H2BE probe oligos form invasive structure on Red FRET oligos



4. Cleavase® enzyme recognizes structure and releases fluorophores from FRET Oligos creating fluorescence signal.



**Figure 1: A graphic representation of the Invader® chemistry in Cervista® HPV HR**

## REAGENTS PROVIDED

**Table 1: Cervista® HPV HR Contents**

Reagent	Vial Label Abbreviation	Vial Quantity & Reagent Volume (REF 92-011)	Vial Quantity & Reagent Volume (REF PRD-01560)	Component Description
HPV Oligo Mix 1	O1 (Blue cap and blue stripe)	1 x 1400 $\mu$ L	8 x 1400 $\mu$ L	Oligonucleotides with affinity to HPV types 51, 56, and 66 suspended in water and MOPS buffer (pH 7.5)
HPV Oligo Mix 2	O2 (Yellow cap and yellow stripe)	1 x 1400 $\mu$ L	8 x 1400 $\mu$ L	Oligonucleotides with affinity to HPV types 18, 39, 45, 59, and 68 suspended in water and MOPS buffer (pH 7.5)
HPV Oligo Mix 3	O3 (Orange cap and orange stripe)	1 x 1400 $\mu$ L	8 x 1400 $\mu$ L	Oligonucleotides with affinity to HPV types 16, 31, 33, 35, 52, and 58 suspended in water and MOPS buffer (pH 7.5)

Cleavase® Enzyme Solution	E (Purple cap and purple stripe)	1 x 1100 µL	8 x 970 µL	Cleavase® Enzyme suspended in 140 mM MgCl <sub>2</sub> , 10 mM Tris (pH 8.0), 25 mM KCl, 0.25% Tween 20, 0.25% Nonidet P40, 25% Glycerol and 0.05 mg/mL BSA
HPV Control 1	C1 (Clear cap and black stripe)	1 x 350 µL	8 x 350 µL	1000 copies/µL cloned HPV type 51 DNA and 3000 copies/µL cloned HIST2H2BE DNA in yeast tRNA and 10 mM Tris, 0.1 mM EDTA Buffer
HPV Control 2	C2 (Clear cap and black stripe)	1 x 350 µL	8 x 350 µL	1000 copies/µL cloned HPV type 18 DNA and 3000 copies/µL cloned HIST2H2BE DNA in yeast tRNA and 10 mM Tris, 0.1 mM EDTA Buffer
HPV Control 3	C3 (Clear cap and black stripe)	1 x 350 µL	8 x 350 µL	1000 copies/µL cloned HPV type 16 DNA and 3000 copies/µL cloned HIST2H2BE DNA in yeast tRNA and 10 mM Tris, 0.1 mM EDTA Buffer
No Target Control	NTC (Clear cap and black stripe)	1 x 350 µL	8 x 350 µL	Yeast tRNA and 10 mM Tris, 0.1 mM EDTA Buffer

## WARNINGS AND PRECAUTIONS

1. For in vitro diagnostic use.
2. Universal safety precautions should be used when handling any human tissues or fluids. Specimens should be disposed according to local requirements.
3. Do not pool reagents from different lots or from different vials of the same lot.
4. Do not use reagents after their expiration date.
5. Product components (product residuals, packaging) can be considered as laboratory waste. Dispose of unused reagents and waste in accordance with applicable federal, state, and local regulations.

## STORAGE AND HANDLING REQUIREMENTS

- Store all reagents between -30°C and -15°C.
- Do not use reagents past expiration date indicated on outside of package.
- Do not store in a “frost-free” freezer.
- Protect from light.
- Prior to use, remove reagents from freezer and allow them to thaw at least 30 minutes at room temperature or until visual inspection indicates that no frozen material is present.
- Vortex reagents prior to each use.
- Hologic recommends no more than six (6) freeze-thaw cycles for all Cervista® HPV HR test reagents.
- Prepare reaction mixes prior to each use. Prepared reaction mixture should be used within 30 minutes.

## **ADDITIONAL REAGENTS AND MATERIALS**

Invader Call Reporter® software is a required component of this IVD test. This software is provided once with the initial order of the Cervista® HPV HR test and, afterwards, when incremental updates to the software are released. Contact your local representative if additional copies are required.

The Genfind® DNA Extraction Kit is an accessory of the Cervista® HPV HR test. Contact your local representative to order the Genfind® DNA Extraction Kit (REF 95-449)

## **MATERIALS REQUIRED, BUT NOT PROVIDED**

### **Consumable Supplies**

- Pipette tips, filter barrier and nuclease-free
- 96-well polypropylene plates
- Clear Plate Sealers
- Mineral oil, molecular biology grade
- 2.0 mL sterile polypropylene tubes and screw caps

### **Equipment**

- Cervista® MTA System for automation users
- Pipettes
- Vortex
- Tecan® Infinite™ F200, Tecan® GENios™, or BioTek® FLx800™ fluorescence plate reader
- Desktop PC with Microsoft® Windows® XP operating system and Microsoft® Excel and Adobe® Reader® software.
- Thermal cycler or oven capable of maintaining appropriate reaction temperatures

## **SPECIMEN COLLECTION, DNA EXTRACTION, AND STORAGE FOR ANALYSIS**

Cervical specimens that may be tested with the Cervista® HPV HR test include the following

- Specimens collected in PreservCyt® Solution, the ThinPrep® Pap test preservation system, using an approved collection device.
- Specimens collected in SurePath™ Preservative Fluid using an approved collection device.

Cervical specimens in PreservCyt® Solution can be stored at room temperature (20 - 30°C) for up to 24 weeks prior to performing the test.

Cervical specimens in SurePath™ Preservative Fluid can be stored at room temperature (20 - 30°C) for up to 6 weeks prior to performing the test.

The Genfind® DNA Extraction Kit (REF 95-449) has been validated for use with the Cervista® HPV HR test. The recommended procedure for DNA extraction from cervical specimens in PreservCyt® Solution or SurePath™ Preservative Fluid is included in the Genfind® DNA Extraction Kit instructions for use.

Laboratories performing the Cervista® HPV HR test with any extraction method other than that provided in the validated Genfind® DNA Extraction Kit are responsible for their own validation of that method.

DNA samples can be stored at 2 to 8°C for up to four weeks. For storage greater than four weeks, place the samples in a freezer between -30°C and -15°C.

## TEST PROCEDURE FOR CERVISTA® MTA SYSTEM

Refer to the Cervista® MTA Operator's Manual (Part Number: MAN-02378-002) for the use of the automated system to perform the Cervista® HPV HR test.

### MANUAL TEST PROCEDURE FOR CERVISTA® HPV HR

#### Reaction Procedure

1. Add 10  $\mu\text{L}$  of each control and sample DNA to three wells of a 96-well plate as indicated in the test plate layout (see Figure 2).

	Mix 1	Mix 2	Mix 3	Mix 1	Mix 2	Mix 3	Mix 1	Mix 2	Mix 3	Mix 1	Mix 2	Mix 3
	1	2	3	4	5	6	7	8	9	10	11	12
A	C1	C1	C1	S5	S5	S5	S13	S13	S13	S21	S21	S21
B	C2	C2	C2	S6	S6	S6	S14	S14	S14	S22	S22	S22
C	C3	C3	C3	S7	S7	S7	S15	S15	S15	S23	S23	S23
D	NTC	NTC	NTC	S8	S8	S8	S16	S16	S16	S24	S24	S24
E	S1	S1	S1	S9	S9	S9	S17	S17	S17	S25	S25	S25
F	S2	S2	S2	S10	S10	S10	S18	S18	S18	S26	S26	S26
G	S3	S3	S3	S11	S11	S11	S19	S19	S19	S27	S27	S27
H	S4	S4	S4	S12	S12	S12	S20	S20	S20	S28	S28	S28

**Figure 2: Cervista® HPV HR test plate layout.**

2. Overlay each well with 20  $\mu\text{L}$  of mineral oil and plate-sealing tape to minimize evaporation.
3. Incubate the samples at 95°C for 5 minutes in a thermal cycler.
4. Mix the reagents and reaction mixes thoroughly and consistently prior to use.
5. Prepare the reaction mixes as indicated in the Mix Preparation sheet (printed from the Invader Call Reporter® software) or according to the calculations in Table 2. Prepare one reaction mix for each of the three HPV Oligo Mixes.

**Table 2. Reaction Mix Preparation Instructions**

Component	$\mu\text{L}/\text{Well}$	Number of Reactions (Samples & Controls ( <i>k</i> ))	25% Overage	Total Volume
HPV Oligo Mix 1, 2, or 3	8 $\mu\text{L}$	<i>K</i>	1.25	=8 <i>k</i> (1.25)
Cleavase® Enzyme Solution	2 $\mu\text{L}$	<i>K</i>	1.25	=2 <i>k</i> (1.25)
<b>Total Mix Volume</b>	<b>10 <math>\mu\text{L}</math></b>	<b><i>K</i></b>	<b>1.25</b>	<b>=10<i>k</i>(1.25) <math>\mu\text{L}</math></b>

6. Decrease thermal cycler temperature setting to 63°C.
7. Add 10  $\mu\text{L}$  of the appropriate reaction mix to each well containing a control or sample (see Figure 2), taking care to pipette below the mineral oil.
8. Incubate the plate at 63°C setting for 4 hours.

#### Data Collection

1. Always bring the plate to room temperature before reading. If the plate cannot be read immediately, store it at 2-8°C (it is recommended to read the plate within 24 hours of test completion).
2. Place the 96-well plate (well A1 must be in the upper left corner) in the plate holder of the fluorescence plate reader. Remove plate-sealing tape.

3. Define the plate type to set up the coordinates and probe height for the specific type of plate. Save the settings.
4. Read the entire plate. Two separate scans are required: FAM (Excitation = 485 nm, Emission = 530 nm) and Red (Excitation = 560 nm, Emission = 612 nm) To detect the HPV signal, the instrument should be set to detect the FAM dye first. To detect the sample genomic DNA, the instrument should be set to detect the Red dye.
5. Adjust the gain of the fluorescence plate reader to be in the linear dynamic range of the reader according to the manufacturer's instructions. The gain should be set so that the No Target Control (NTC) yields values that are in the background range of the reader, with a minimum RFU of 600. The NTC values do not have to be identical for the FAM and Red reads.

## **PROCEDURAL NOTES AND PRECAUTIONS**

1. Laboratories should use good laboratory practices and comply with all applicable federal, state and local regulatory requirements.
2. Mix the samples, reagents, and reaction mixes thoroughly and consistently.
3. Use nuclease-free, sterile disposable aerosol barrier pipette tips for each addition and transfer to avoid cross-contamination.
4. Use nuclease-free, disposable polypropylene tubes for preparing the reaction mixes.
5. Verify that the 96-well plate type is compatible with the specific thermal cycler and fluorescence plate reader to be used before starting the test.\*
6. Use only calibrated equipment.
7. Controls must be added to the designated positions on the test plate layout shown in Figure 2 in order for the Invader Call Reporter® software to function properly.
8. Use fresh mineral oil for each reaction setup (do not transfer these reagents back to the original container once they have been dispensed).
9. Refer to the test plate layout to ensure that the correct mix is added to the appropriate column.\*
10. Always place the pipette tip near the bottom of the well to ensure that the reaction mix is added below the mineral oil. Mix by carefully filling and emptying the pipette tip 3 – 5 times.\*

\*Procedural Notes 5, 9 and 10 do not apply to the Cervista® MTA system

## **INTERPRETATION OF RESULTS**

A signal to noise value (sample signal measured against signal from a No Target Control reaction well) is generated for each of the three reactions. This signal to noise value is referred to as FOZ (Fold-Over-Zero). A final positive or negative or indeterminate result for any particular sample is generated based on the analysis of three separate reaction wells.

The ratio between HPV FOZ values generated by the three reaction mixtures determines whether a sample is positive. The HPV FOZ ratio is calculated by dividing the highest HPV FOZ value from any one of the three reaction mixtures by the lowest HPV FOZ value of the three. When any FOZ value is less than 1, it is rounded up to 1 for the ratio calculation. If the HPV FOZ Ratio is greater than or equal to 1.525, then the sample is positive for HPV. However, in a subset of mixed infections, all three reaction wells may generate a signal much higher than background. In some cases, these mixed infections may generate positive signals of similar intensity in all three reaction wells and therefore a HPV FOZ Ratio of less than 1.525. In order to avoid the chance of a false negative due to the triple positive scenario described above, a second calculation is applied as follows: when the FOZ ratio is less than 1.525, but all three individual reaction FOZ values are greater than or equal to a second cutoff value of 1.93, the sample is positive for HPV.



An indeterminate call is generated in three different scenarios 1) when the % CV between the gDNA FOZ values is  $\geq 25.0\%$  (High % CV), 2) when all three HPV FOZ values are  $< 0.7$  (Low HPV FOZ) and 3) when average gDNA FOZ of a negative sample is  $< 1.5$  (low gDNA).

A summary of the sample call criteria described above is shown in Figure 3.

### Terminology

- HPV FOZ:** For each HPV Oligo Mix, the FAM signal of the sample divided by the FAM signal of the No Target Control.
- HPV FOZ Ratio:** The highest HPV FOZ of the three HPV Oligo Mixes divided by the lowest HPV FOZ of the three HPV Oligo Mixes (normalized to 1.0 if FOZ is lower than 1.0).
- Average gDNA FOZ:** The average value determined from the three genomic DNA FOZ values obtained from each of the three reaction mixes, calculated by dividing the Red signal of the sample by the Red signal of the No Target Control.
- %CV gDNA FOZ:** % coefficient of variation for the gDNA FOZ values generated by the three HPV Oligo Mixes.




Figure 3: Sample Call Criteria Ordered Top to Bottom

### QUALITY CONTROL

#### Negative Control

- The No Target Control must yield the appropriate results in order for the samples on that plate to be valid. If it does not meet these criteria, the samples and controls on that plate are invalid and must be repeated (see Table 3).
- The minimum signal for each of the three mixes must be greater than or equal to 600 RFU ( $\geq 600$ ).

3. The %CV of the average HPV signal from all three mixes must be less than 25.0% (<25.0%), or the samples and controls on that plate are invalid and must be repeated (See Table 3).
4. The %CV of the average gDNA signal from all three mixes must be less than 25.0% (<25.0%).

**Table 3: No Target Control Criteria**

<b>Result</b>	<b>Min. HPV Signal</b>	<b>Min. gDNA Signal</b>	<b>Max. % CV (HPV and gDNA)</b>
Valid	600	600	24.9%

### HPV Controls

1. HPV controls (HPV Controls 1-3) must yield the appropriate results for the test to be valid. If controls do not meet these criteria, the samples on that plate are also invalid and must be repeated (See Table 4).
2. A HPV FOZ Ratio is determined by dividing the highest HPV FOZ of the three reaction mixes by the lowest HPV FOZ of the three (normalized to 1.0 if lower than 1.0). HPV Control 1 should yield a positive HPV FOZ value ( $\geq 1.525$ ) for only HPV Oligo Mix 1, HPV Control 2 should yield a positive HPV FOZ value ( $\geq 1.525$ ) for only HPV Oligo Mix 2, and HPV Control 3 should yield a positive HPV FOZ value ( $\geq 1.525$ ) for only HPV Oligo Mix 3.
3. The Mean gDNA FOZ of all three mixes must be greater than or equal to 1.50 ( $\geq 1.50$ ), or the control is invalid for low gDNA.
4. The %CV of the Mean gDNA FOZ from all three mixes should be less than 25.0% (<25.0%).

**Table 4: HPV Control and Sample Criteria**

<b>Control</b>	<b>Result</b>	<b>HPV FOZ Ratio</b>	<b>Positive FOZ Mix</b>	<b>Average gDNA FOZ</b>	<b>% CV gDNA FOZ</b>
HPV Control 1	Valid Control	$\geq 1.525$	Mix 1 only	$\geq 1.50$	< 25.0%
HPV Control 2	Valid Control	$\geq 1.525$	Mix 2 only	$\geq 1.50$	< 25.0%
HPV Control 3	Valid Control	$\geq 1.525$	Mix 3 only	$\geq 1.50$	< 25.0%

### Test Verification

1. Sample results are valid when both positive and negative controls yield correct results. If the No Target Control (negative control) is invalid and/or any result for positive control(s) is invalid, all sample results on that plate are invalid and must be repeated. Refer to the Troubleshooting sections located in the Instruction-For-Use and in the Software User Manual For Invader Call Reporter® software. Refer to the Troubleshooting section of the Cervista® MTA Operators Manual (Part Number MAN-02378-002) for the Cervista® MTA system.
2. All quality control requirements should be performed in conformance with local, state, and federal regulations as well as accreditations requirements.

### LIMITATIONS

1. The Cervista® HPV HR test detects DNA of high-risk HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68. This test does not detect DNA of HPV low-risk types (e.g. 6, 11, 42, 43, 44).
2. The Cervista® HPV HR test exhibits cross-reactivity to two HPV types of unknown risk. An HPV positive result was observed with 5000 copies/reaction of HPV type 67 and 50,000 copies/reaction of HPV type 70.

3. A negative result does not exclude the possibility of HPV infection because very low levels of infection or sampling error may cause a false-negative result.
4. The test has been validated for use only with cervical cytology specimens collected in PreservCyt<sup>®</sup> Solution or SurePath<sup>™</sup> Preservative Fluid.
5. The performance of the Cervista<sup>®</sup> HPV HR test was established using DNA extracted with the Genfind<sup>®</sup> DNA Extraction Kit.
6. Interference was observed in cervical specimens collected into PreservCyt<sup>®</sup> Solution contaminated with high levels (2%) of contraceptive jelly and/or anti-fungal creams when DNA was isolated with the Genfind<sup>®</sup> DNA Extraction Kit. Under these conditions, false-negative results may be obtained.
7. Interference was observed in cervical specimens collected into SurePath<sup>™</sup> Preservative Fluid contaminated with contraceptive jelly and/or anti-fungal creams at levels of 0.5% and the personal lubricant ASTROGLIDE<sup>®</sup> at levels of 0.5% when DNA was isolated with the Genfind<sup>®</sup> DNA Extraction Kit. Under these conditions, false-negative results may be obtained. The potential interference of the personal lubricant ASTROGLIDE<sup>®</sup> was not tested in cervical specimens collected into PreservCyt<sup>®</sup> Solution

## PERFORMANCE CHARACTERISTICS

### Clinical Trial Performance

A multi-center, cross-sectional and prospective clinical study was conducted to evaluate the performance of the Cervista<sup>®</sup> HPV HR test for the detection of human papillomavirus and cervical intraepithelial neoplasia grade 2 or higher (CIN2+) in liquid cytology samples. Residual ThinPrep<sup>®</sup> cytology specimens were collected from 3,540 women undergoing routine cervical cancer screening. This study included 2,026 women age 30 and over with normal cytology results (WNL) and 1,514 women age 18 and over with ASC-US results. Cytology samples were collected from 89 clinical sites across the United States. DNA was extracted from residual ThinPrep<sup>®</sup> cervical samples that remained after routine cervical cancer screening procedures were completed. The DNA was subsequently tested using the Cervista<sup>®</sup> HPV HR test.

The analytical performance of the test was measured against PCR/Sequencing results. Residual DNA samples from both ASC-US and WNL subjects were used for PCR amplification and sequencing. DNA samples were amplified using consensus primers for the HPV L1 gene. A portion of the human beta-globin gene was also amplified as an internal control. Purified amplicons were used as templates in multiple sequencing reactions for 14 high-risk types of HPV: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68. The sequencing data was analyzed using various sequence alignment software.

A comparison of the Cervista<sup>®</sup> HPV HR test with the PCR/Sequencing method among both ASC-US and WNL subjects resulted in an overall 86.1% agreement between the two methods (95% CI = 84.9 - 87.3%). The positive percent agreement between the two methods was 91.8 (89.7 – 93.6%) and the negative percent agreement was 84.2% (95% CI = 82.7 – 85.7).

The clinical performance of the Cervista<sup>®</sup> HPV HR test was measured against colposcopy and histology results. Biopsy samples were collected from women with ASC-US cytology as warranted by standard of care guidelines at each participating clinical site. Consensus histology results provided by a central review panel served as the “gold standard” for determining the presence or absence of disease. In the absence of histology data, the lack of colposcopically visible cervical lesions and no biopsy equated to the absence of disease.

There were 1347 ASC-US subjects with known disease status (central histology or negative colposcopy) and Cervista<sup>®</sup> HPV HR results. A comparison of the Cervista<sup>®</sup> HPV HR results with Colposcopy/Central Histology is shown in Tables 5 and 6.

**Table 5:** Cervista® HPV HR versus Colposcopy/Consensus Histology results (CIN2+) among women with ASC-US cytology

Cervista® HPV HR	Colposcopy/ Histology		
	Positive <sup>b</sup>	Negative <sup>c</sup>	Total
Positive	64	705	769
Negative <sup>a</sup>	5	573	578
Total	69	1278	1347

<sup>a</sup> Includes indeterminate results

<sup>b</sup> CIN2+ Histology

<sup>c</sup> No CIN or CIN1 by Central Histology or Colposcopy without Central Histology

**Table 6:** Cervista® HPV HR versus Colposcopy/Consensus Histology results (CIN3+) among women with ASC-US cytology

Cervista® HPV HR	Colposcopy/ Histology		
	Positive <sup>b</sup>	Negative <sup>c</sup>	Total
Positive	22	705	727
Negative <sup>a</sup>	0	573	573
Total	22	1278	1300

<sup>a</sup> Includes indeterminate results

<sup>b</sup> CIN3+ including one adenocarcinoma in situ

<sup>c</sup> No CIN, CIN1 or CIN2 by Central Histology or Colposcopy without Central Histology

Among women with ASC-US cytology the clinical sensitivity of the test for CIN2+ was 92.8% (95% CI = 83.9% - 97.6%) and the negative predictive value was 99.1% (95% CI = 98.0 - 99.7). The clinical sensitivity and the negative predictive values of the test for CIN 3 are both 100% (95% CI = 84.6% -100% and 99.4% - 100%).

There are a number of key variables that are known to influence the performance characteristics of any HPV test in a clinical study. These include, but are limited to, cervical sampling techniques, the quality of the cytology results, age of the population tested, disease prevalence, disease ascertainment methods and methods for histological interpretation. Given the number of variables present during routine HPV testing across multiple clinical sites, it is noteworthy that many of the results obtained from the Hologic clinical trial are similar to those seen under the controlled trial conditions described in the ASC-US/LSIL Triage Study (ALTS).<sup>7,4</sup> A comparison of the study design, disease prevalence and clinical performance characteristics for the Hologic study and ALTS is shown in Table 7. The difference in CIN2+ rates observed between the two studies may reflect population differences as well as disease ascertainment differences.

**Table 7:** Comparison of Hologic Clinical Trial and ALTS<sup>7,4</sup>

Criterion	ALTS	Hologic
Number of Enrollment Sites / States	4 / 4	89 / 22
Mean Age of Subjects	29	33
Subjects with colposcopy completed	1149 <sup>a</sup>	1347 <sup>b</sup>
Subjects with no lesion; no biopsy performed (%)	25%	28%
Subjects with no pathologic lesion on biopsy (%)	49%	53%
Subjects with CIN1 (%)	15%	14%
Subjects with CIN2+ (%)	11%	5%
Detection rate for CIN2+	96%	93%
Detection rate for CIN3+	96%	100%
Negative Predictive Value for CIN2+	98.9%	99.1%
Negative Predictive Value for CIN3+	99.5%	100.0%
Referral rate to colposcopy	57%	57% <sup>c</sup>
PCR concordance	82.7%	86.1%

<sup>a</sup> Immediate colposcopy arm of ALTS

<sup>b</sup> Number of subjects with known disease status and Cervista® HPV HR results

<sup>c</sup> Referral rate for women 30 years of age and older was 43%

## Analytical Sensitivity

Cloned HPV plasmid DNA, representing the 14 HPV types detected by the Cervista® HPV HR test, was tested to determine the individual analytical sensitivity for each specific type. Individual Limit of Detection (LoD) values were calculated for the 14 HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68) as a function of a Limit of Blank (LoB) measurement and a population variance measurement ( $SD_s$ ) from multiple concentrations of the specific HPV target (CLSI/NCCLS guideline EP17-A Vol. 24 No. 34). Nine HPV-negative characterized DNA samples isolated from cervical specimens were used to determine the LoB value (FAM FOZ Ratio = 1.20). Each HPV plasmid DNA was tested at concentrations of 7500, 5000, 2500, and 1250 copies per reaction, each in a background of three genomic DNA concentrations isolated from an HPV-negative cell line (10 ng, 100 ng, and 1  $\mu$ g per reaction). All positive and negative samples were tested in replicates of eight.

The Limit of Detection for each HPV type is referenced in Table 8. Limits are described in terms of the FAM FOZ Ratio and as a copy number range.

**Table 8:** Cervista® HPV HR Test Analytical Sensitivity Summary

HPV DNA Type	LoD (Copy Number/Reaction)	LoD (FAM FOZ Ratio)	$SD_s$
16	1250-2500	1.34	0.08
18	1250-2500	1.34	0.08
31	1250-2500	1.30	0.06
33	2500-5000	1.31	0.07
35	5000-7500	1.34	0.09
39	2500-5000	1.30	0.06
45	1250-2500	1.31	0.06
51	2500-5000	1.35	0.09
52	1250-2500	1.28	0.04
56	1250-2500	1.37	0.10
58	2500-5000	1.35	0.09
59	2500-5000	1.35	0.09
66	2500-5000	1.30	0.06
68	2500-5000	1.30	0.06
<b>Mean</b>		<b>1.324</b>	<b>0.074</b>

## Accuracy and Specificity Compared to a PCR / DNA Sequencing Method

A study designed to evaluate the ability of the Cervista® HPV HR test to detect High-Risk HPV DNA from clinical specimens was performed. The specimens were characterized using a research-use HPV genotyping method that utilized degenerate PCR amplification followed by HPV type-specific sequencing. The PCR/sequencing method was used as the sole determinant for the presence of HPV DNA.

The study involved 192 specimens stored in PreservCyt® Solution, of which 189 had clear sequencing results. Of these 189 samples, two samples were indeterminate by the Cervista® HPV HR test. Indeterminate results were not included in the comparative analysis of the Cervista® HPV HR test and PCR/sequencing methods.

The proportion of PCR/sequencing negative results that were positive by the Cervista® HPV HR test was 5/187. Conversely, the proportion of PCR/sequencing positive results that were negative by the Cervista® HPV HR test was 11/187 (see Table 9).

When analyzed in this manner, an overall 91.4% agreement (171/187; 95% CI = 86.5-95.0) was observed between the methods, with a positive and negative agreement of 89.8% and 93.7%, respectively (95% CI = 82.5-94.8 and 85.8-97.9).

**Table 9:** Detection of HPV DNA Comparing Cervista® HPV HR Test to PCR with Type-Specific Sequencing

		PCR/Sequencing		
		Negative	Positive	Total
Cervista® HPV HR test	Negative	74	11	85
	Positive	5	97	102
	Total	79	108	187

## Reproducibility

In this investigational study, overall reproducibility of the Cervista® HPV HR test was assessed at three sites using a panel of HPV positive and negative cultured cells and HPV positive and negative cervical specimens. DNA was extracted from 2 mL of cervical specimen or cultured cells suspended in PreservCyt® Solution. The DNA was extracted using the Genfind® DNA Extraction Kit. Sixteen samples were tested at three locations on five non-consecutive days within a two-week time period. Two lots of Cervista® HPV HR kits and three lots of Genfind® DNA Extraction Kits were used for the study.

Within day/site agreement was assessed by calculating the between run percent agreement for the three possible pairings within each of the days/sites. The average percent agreement and one-sided exact 95% confidence interval is presented first for each site (intra-site reproducibility), then across all three sites (inter-site reproducibility).

Between day/within site agreement was assessed by calculating the between run % agreement for any two runs done on two separate days within a site for all possible pairings. The average percent agreement and one-sided exact 95% confidence interval is presented first for each site (intra-site, inter-run reproducibility), then across all three sites (inter-site, inter-run reproducibility).

Between site agreement was assessed by calculating the between run percent agreement for any two runs done by two different sites for all possible pairing [n=3 (sites 1 and 2, sites 1 and 3, sites 2 and 3)]. The average percent agreement and one-sided 95% confidence interval are presented in Tables 10 and 11.

**Table 10:** HPV HR Molecular Assay Between-Day (Within-Site) Percent Agreement

Site	Number of Comparisons	Number of Agreements	Percent Agreement	1-sided 95% Confidence Lower Limit
Site 1	200	200	100.0%	96.3%
Site 2	200	193	96.5%	90.8%
Site 3	200	200	100.0%	96.3%
Across All 3 Sites	600	593	98.8%	96.9%

**Table 11:** HPV HR Molecular Assay Between-Site Percent Agreement

Sites	Number of Comparisons	Number of Agreements	Percent Agreement	1-sided 95% Confidence Lower Limit
Site 1 vs. Site 2	500	490	98.0%	96.6%
Site 1 vs. Site 3	500	500	100.0%	99.4%
Site 2 vs. Site 3	500	490	98.0%	96.6%
All Site Pairs	1500	1480	98.7%	97.9%

## Interfering Substances

Four cervical specimens (one HPV negative, three HPV positive) and three cell line samples (one HPV negative, two HPV positive) were tested with added substances that potentially could be present in the cervical specimen. The substances that were added to the specimens included PreservCyt® Solution, two types of vaginal douches, contraceptive jelly, two types of anti-fungal creams, and negative clinical specimens that visually contained blood and mucous. The PreservCyt® Solution, douche, contraceptive jelly and anti-fungal creams were added at two levels, 0.5% and 2%. These levels were chosen in order to represent extreme situations that could potentially occur during specimen collection if the cervix was not cleared prior to obtaining the specimen. DNA was isolated from pure and impure samples using the Genfind® DNA Extraction Kit and was tested with the Cervista® HPV HR test to assess interference caused by the introduced substances.

Contraceptive jelly and the anti-fungal creams containing either clotrimazole or miconazole at a 2% sample concentration resulted in indeterminate and false negative results. During DNA extraction, the contraceptive jelly interfered with the magnetic bead separation in the 10 mM Tris buffer, causing low DNA recovery and insufficient DNA sample for testing. This interference was visually detectable.

The levels of the above substances that are required to cause testing failure are unusually high and should not be encountered in actual clinical specimens if the clinician follows the proper Pap sampling procedure of clearing the cervix before obtaining the cell sample for Pap analysis.

The Cervista® HPV HR test was also tested with components that could potentially be transferred inadvertently during sample extraction using the Genfind® DNA Extraction Kit. DNA containing three levels (0, 5% and 10%) each of 70% ethanol or Genfind® magnetic beads was tested to assess interference caused by the introduced substances. Interference was observed when 10% of the DNA sample volume contained either 70% ethanol or the magnetic beads.

## Cross-Reactivity

A panel of bacteria, fungi, and viruses commonly found in the female anogenital tract, as well as several cloned Human papillomavirus types of low or undetermined risk were tested with the Cervista® HPV HR test to assess potential cross-reactivity (see Tables 12-14).

**Table 12:** The organisms listed below were added to PreservCyt® Solution at concentrations of approximately  $1 \times 10^5$  cfu/mL and  $1 \times 10^7$  cfu/mL. DNA from these organisms and a negative cell line (Jurkat,  $1 \times 10^5$  cells/mL) was extracted using the Genfind® DNA Extraction Kit. All samples yielded negative results with the Cervista® HPV HR test.

<i>Candida albicans</i>	<i>Proteus vulgaris</i>
<i>Corynebacterium pseudodiphtheriticum</i>	<i>Staphylococcus aureus</i>
<i>Enterococcus faecalis</i>	<i>Staphylococcus epideridis</i>
<i>Escherichia coli</i>	<i>Streptococcus mitis</i>
<i>Lactobacillus acidophilus</i>	<i>Streptococcus pyogenes</i>

**Table 13:** Purified DNA obtained from the organisms listed below was tested at concentrations of  $1 \times 10^5$  copies/reaction and  $1 \times 10^7$  copies/reaction using the Cervista® HPV HR test. All samples yielded negative results.

Herpes simplex virus, type 1 (HSV-1)	<i>Chlamydia trachomatis</i>
Herpes simplex virus, type 2 (HSV-2)	<i>Neisseria gonorrhoeae</i>
Human Immunodeficiency Virus type 1 (HIV-1, pol and env regions)	<i>Neisseria meningitides</i>
	<i>Mycoplasma hominis</i>

**Table 14:** Purified cloned DNA or PCR amplicon samples for the following HPV types were tested at concentrations of  $1 \times 10^5$  copies/reaction and  $1 \times 10^7$  copies/reaction, unless noted, using the Cervista® HPV HR test. All samples yielded negative results.

Human papillomavirus type 1a	Human papillomavirus type 44
Human papillomavirus type 6	Human papillomavirus type 53
Human papillomavirus type 11	Human papillomavirus type 67*
Human papillomavirus type 42	Human papillomavirus type 70*
Human papillomavirus type 43	Human Internal Control gene

\*Human papillomavirus types 67 and 70 yielded positive results with the Cervista® HPV HR test at  $1 \times 10^5$  and  $1 \times 10^7$  copies/reaction. Upon further titration of these samples, negative results were obtained with the Cervista® HPV HR test at  $1 \times 10^3$  copies/reaction and  $1 \times 10^4$  copies/reaction respectively.

In addition, DNA extracted from a panel of twelve cervical specimens that were stored in PreservCyt® Solution and previously confirmed to contain HPV types of low or undetermined risk (HPV Types 6, 42, 43, 44, 53 or 70) by PCR/sequencing was also tested and yielded negative results with the Cervista® HPV HR test.

## Precision

Repeatability and within-laboratory precision of the Cervista® HPV HR test was demonstrated in a 21-day study with three alternating operators, each performing two runs per day on individually-assigned sets of equipment. Each run consisted of four plates. Different plate layouts were used for the runs within a day.

Each run consisted of genomic DNA samples isolated from two HPV positive cell lines (SiHa - Type 16 and HeLa - type 18), an HPV negative cell line (Jurkat) and contrived samples containing HPV16, HPV18, HPV31, HPV33, HPV35, HPV39, HPV45, HPV51, HPV52, HPV56, HPV58, HPV59, HPV66 or HPV68 plasmid DNA and Jurkat DNA. Each sample was tested in duplicate at three concentrations.

At 2500 copies/reaction, the plasmid DNA samples yielded 57.4% (675/1176) positive results. At 5000 copies/reaction the plasmid DNA samples yielded 97.2% (1143/1176) positive results. At 10000 copies/reaction, the plasmid DNA samples yielded 100.0% (1176/1176) positive results (see Table 15).

**Table 15:** Summary of positive and negative values for each sample condition tested.

Target	Copies/Reaction <sup>a</sup> or Cells/mL Extracted <sup>b</sup>	N	HPV Positive n (%)	HPV Negative n (%)
HPV 16	2,500 <sup>a</sup>	84	82 (98%)	2 (2%)
	5,000 <sup>a</sup>	84	84 (100%)	0 (0%)
	10,000 <sup>a</sup>	84	84 (100%)	0 (0%)
HPV 18	2,500 <sup>a</sup>	84	64 (76%)	20 (24%)
	5,000 <sup>a</sup>	84	84 (100%)	0 (0%)
	10,000 <sup>a</sup>	84	84 (100%)	0 (0%)
HPV 31	2,500 <sup>a</sup>	84	58 (69%)	26 (31%)
	5,000 <sup>a</sup>	84	84 (100%)	0 (0%)
	10,000 <sup>a</sup>	84	84 (100%)	0 (0%)
HPV 33	2,500 <sup>a</sup>	84	13 (15%)	71 (84%)
	5,000 <sup>a</sup>	84	81 (96%)	3 (4%)
	10,000 <sup>a</sup>	84	84 (100%)	0 (0%)
HPV 35	2,500 <sup>a</sup>	84	1 (1%)	83 (99%)



Target	Copies/Reaction <sup>a</sup> or Cells/mL Extracted <sup>b</sup>	N	HPV Positive n (%)	HPV Negative n (%)
	5,000 <sup>a</sup>	84	60 (71%)	24 (29%)
	10,000 <sup>a</sup>	84	84 (100%)	0 (0%)
HPV 39	2,500 <sup>a</sup>	84	52 (62%)	32 (38%)
	5,000 <sup>a</sup>	84	84 (100%)	0 (0%)
	10,000 <sup>a</sup>	84	84 (100%)	0 (0%)
HPV 45	2,500 <sup>a</sup>	84	84 (100%)	0 (0%)
	5,000 <sup>a</sup>	84	84 (100%)	0 (0%)
	10,000 <sup>a</sup>	84	84 (100%)	0 (0%)
HPV 51	2,500 <sup>a</sup>	84	77 (92%)	7 (8%)
	5,000 <sup>a</sup>	84	84 (100%)	0 (0%)
	10,000 <sup>a</sup>	84	84 (100%)	0 (0%)
HPV 52	2,500 <sup>a</sup>	84	21 (25%)	63 (75%)
	5,000 <sup>a</sup>	84	84 (100%)	0 (0%)
	10,000 <sup>a</sup>	84	84 (100%)	0 (0%)
HPV 56	2,500 <sup>a</sup>	84	64 (76%)	20 (24%)
	5,000 <sup>a</sup>	84	83 (99%)	1 (1%)
	10,000 <sup>a</sup>	84	84 (100%)	0 (0%)
HPV 58	2,500 <sup>a</sup>	84	60 (71%)	24 (29%)
	5,000 <sup>a</sup>	84	84 (100%)	0 (0%)
	10,000 <sup>a</sup>	84	84 (100%)	0 (0%)
HPV 59	2,500 <sup>a</sup>	84	16 (19%)	68 (81%)
	5,000 <sup>a</sup>	84	79 (94%)	5 (6%)
	10,000 <sup>a</sup>	84	84 (100%)	0 (0%)
HPV 66	2,500 <sup>a</sup>	84	40 (48%)	44 (52%)
	5,000 <sup>a</sup>	84	84 (100%)	0 (0%)
	10,000 <sup>a</sup>	84	84 (100%)	0 (0%)
HPV 68	2,500 <sup>a</sup>	84	43 (51%)	41 (49%)
	5,000 <sup>a</sup>	84	84 (100%)	0 (0%)
	10,000 <sup>a</sup>	84	84 (100%)	0 (0%)
SiHa/Jurkat	2500 SiHa / 97,500 Jurkat <sup>b</sup>	84	0 (0%)	84 (100%)
	5000 SiHa / 95,000 Jurkat <sup>b</sup>	84	15 (18%)	69 (82%)
	20,000 SiHa / 80,000 Jurkat <sup>b</sup>	84	84 (100%)	0 (0%)
HeLa/Jurkat	1,250 HeLa / 98,750 Jurkat <sup>b</sup>	84	65 (77%)	19 (23%)
	2,500 HeLa / 97,500 Jurkat <sup>b</sup>	84	84 (100%)	0 (0%)
	10,000 HeLa / 90,000 Jurkat <sup>b</sup>	84	84 (100%)	0 (0%)
Jurkat	10,000 <sup>b</sup>	84	2 (2%)	82 (98%)
	20,000 <sup>b</sup>	84	0 (0%)	84 (100%)
	100,000 <sup>b</sup>	84	0 (0%)	84 (100%)

### Performance of the Cervista<sup>®</sup> HPV HR test on specimens collected into SurePath<sup>™</sup> Preservative Fluid compared to specimens collected into PreservCyt<sup>®</sup> Solution

A total of 418 subjects were enrolled in a co-collection study to obtain paired cervical specimens collected into SurePath<sup>™</sup> Preservative Fluid and PreservCyt<sup>®</sup> Solution from each subject. Each pair of specimens was tested with the Cervista<sup>®</sup> HPV HR test. A total percent agreement of 92% was observed for the results obtained for specimens collected into the SurePath<sup>™</sup> Preservative Fluid compared to the results obtained for specimens collected into the PreservCyt<sup>®</sup> Solution.

**Table 16:** Summary of Cervista® HPV HR results from cervical specimens co-collected into SurePath™ Preservative Fluid and PreservCyt® Solution

	<b>SurePath™ Specimen Results</b>	<b>PreservCyt® Specimen Results</b>
Total	418	418
% Positive	29.4%	29.2%
% Negative	69.9%	70.6%
% Indeterminate	0.7%	0.2%

## References

1. National Cancer Institute website: [www.cancer.gov](http://www.cancer.gov) (2008).
2. Meijer CJ, Snijders PJ, and Castle PE. 2006. Clinical utility of HPV genotyping. *Gynecol Oncol* 103: 12-17.
3. Wright TC, Jr., Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, and Solomon D. 2007. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. *Am J Obstet Gynecol* 197(4): 346-55.
4. Sherman ME, Schiffman M, and Cox TJ. 2002. Effects of age and human papilloma viral load on colposcopy triage: data from the randomized Atypical Squamous Cells of Undetermined Significance/Low-grade Squamous Intraepithelial Lesion Triage Study (ALTS). *Jour Nat Can Inst* 94(2): 102-107.
5. Davey DD, Neal MH, Wilbur DC, Colgan TJ, Styer PE, and Mody DR. 2004. Bethesda 2001 implementation and reporting rates: 2003 practices of participants in the college of American Pathologists Interlaboratory Comparison Program in Cervicovaginal Cytology. *Arch Path Lab Med* 128: 1224-1229.
6. Wright TC, Jr., Cox JT, Massad LS, Twiggs LB, Wilkinson EJ. 2001 Consensus Guidelines for the management of women with cervical cytological abnormalities. *JAMA* 2002; 287: 2120-2129.
7. Solomon D, Schiffman M, and Tarone R. 2001. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. *Jour Nat Can Inst*; 93(4): 293-299.
8. Mayrand MH, E Duarte-Franco, I Rodrigues, SD Walter, J Hanley. 2007. A Ferenczy, S Ratnam, F Coutlée, EL Franco. Human Papillomavirus DNA versus Papanicolaou Screening Tests for Cervical Cancer. *N Engl J Med* 357(16): 1579-1588.
9. Wheeler CM, WC Hunt, M Schiffman, PE Castle. 2006. Human papillomavirus genotypes and the cumulative 2-Year risk of cervical cancer. *J Infect Dis* 194: 1291-1299.
10. Saslow D, Runowicz CD, Solomon D, Moscicki A-B, Smith RA, Eyre HJ, Cohen C. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. *CA Can Jour Clin* 2002; 53: 342-362.
11. Wright TC Jr, Schiffman M, Solomon D, Cox JT, Garcia F, Goldie S, Hatch K, Noller KL, Roach N, Runowicz C, Saslow D. 2004. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. *Obstet Gynecol* 103: 304-309.
12. Hall JG, Eis PS, Law SM, Reynaldo LP, Prudent JR, Marshall DJ, Allawi HT, Mast AL, Dahlberg JE, Kwiatkowski RW, de Arruda M, Neri BP, and Lyamichev VI. 2000. Sensitive detection of DNA polymorphisms by the serial invasive signal amplification reaction. *PNAS* 97(15): 8272-8277.

# TROUBLE SHOOTING GUIDE: MANUAL TEST PROCEDURE FOR CERVISTA® HPV HR

**Table 17:** Troubleshooting Guide

Problem	Potential Cause	Possible Solution
Insufficient volume made for reaction mixes	Number of samples entered in “Assay Selection” tab of software is less than samples added to the plate	Manually recalculate the required amount of reaction mix needed to complete the entire plate.
		Recreate software printouts using correct number of samples.
	Excess reaction mix volume added to 96 well microplate.	Verify the correct reaction mix volumes were added to each well.
		Verify the calibration information on equipment is current.
No Target Control displays the following results: <ul style="list-style-type: none"> <li>• Increase gain for scan 1</li> <li>• Increase gain for scan 2</li> <li>• Increase gain for both scans</li> </ul>	Fluorescence microplate reader gain settings are too low causing the raw fluorescent signal values to fall below the minimum requirement	Increase the fluorometer gain settings for the designated scan(s) so that the No Target Control produces a minimum signal of 600 RFU and re-read the plate.
Errors occur during data import: "Check FAM & Red gain settings and read the whole plate again. (Partial plate reads are not allowed.)" "Check FAM gain setting and read the whole plate again. (Partial plate reads are not allowed.)" "Check Red gain setting and read the whole plate again. (Partial plate reads are not allowed.)"	Fluorometer issues	See Troubleshooting Guide in the Invader Call Reporter® Software User Manual, for fluorometer issues that may contribute to this error.
	Incubation period was longer than the specified length of time recommended.	Confirm that the incubation was performed for the specified length of time and at the specified temperature.
No Target Control displays the following results: High %CV (HPV NTC)	Insufficient or inconsistent mixing of reagents.	<ul style="list-style-type: none"> <li>• Be sure all samples, reagents and reaction mixes are mixed thoroughly.</li> <li>• When adding reaction mix to each well, place tips at the bottom of the well (beneath mineral oil) and slowly pipette up and down</li> </ul>

High %CV (gDNA NTC)	Incorrect preparation of reaction mixes.	3-4 times. <ul style="list-style-type: none"> <li>• Verify all liquid is expelled from the pipette tip during additions.</li> <li>• Verify the correct reagent was added to each well.</li> </ul>
	Inconsistent addition of the No Target Control or reaction mix to the microplate.	<ul style="list-style-type: none"> <li>• Verify the correct reagent volumes were added to each well.</li> <li>• Verify the calibration information on equipment is current.</li> <li>• Visually inspect plate for consistent volumes between wells.</li> </ul>
	Suspected contamination during sample addition or reaction mix preparation	<ul style="list-style-type: none"> <li>• Use nuclease-free aerosol barrier tips and sterile tubes when making the reaction mixes.</li> <li>• Wear gloves when setting up the test.</li> <li>• Make sure that pipette tips touch only the solution being dispensed.</li> <li>• Do not touch pipette tips with hands.</li> <li>• Clean lab surfaces using appropriate materials</li> </ul>
	Sample evaporation	Verify mineral oil addition to each well.
	Bubbles in the reaction plate wells	If possible, spin down plates prior to fluorescence scanning.
	Prepared reaction mixes were not used within recommended time period	Use reaction mixes within 30 minutes of preparation.
Control(s) displays “Invalid Control” result	Insufficient or inconsistent mixing of controls	<ul style="list-style-type: none"> <li>• Be sure all controls and reagents are mixed thoroughly and consistently.</li> <li>• When adding reaction mix to each well, place tips at the bottom of the well (beneath mineral oil) and slowly pipette up and down 3-4 times.</li> </ul>
	Inconsistent addition of reaction mix	<ul style="list-style-type: none"> <li>• Make sure that all liquid is expelled from the pipette tip during additions.</li> <li>• Verify that the correct control was added to each well.</li> </ul>
	Insufficient or Inconsistent addition of control	<ul style="list-style-type: none"> <li>• Verify that the correct control volume was added to each well.</li> <li>• Verify the calibration information on equipment.</li> <li>• Visually inspect plate for consistent volumes between wells.</li> </ul>
	Correct control(s) was not added to the plate or was not added to the correct plate position.	Verify the correct controls were added to the correct plate positions.

	Incubation period was shorter or longer than the specified length of time recommended.	Confirm that the incubation was performed for the specified length of time and at the specified temperature.
	Suspected contamination during sample addition.	Use nuclease-free aerosol barrier tips and sterile tubes during set up.
		Wear gloves when setting up the test.
		Make sure that pipette tips touch only the solution being dispensed.
		Do not touch pipette tips with hands.
		Clean lab surfaces using appropriate materials.
	Sample evaporation	Verify mineral oil addition to each well.
	Improper plate orientation	When scanning the plate, orient the plate so well A-1 is in the upper left-hand corner.
	Bubbles in the reaction plate wells	If possible, spin down plates prior to fluorescence scanning.
Sample displays "IND: High %CV" result.	Prepared reaction mixes were not used within recommended time period.	Use reaction mixes within 30 minutes of preparation.
	Insufficient or inconsistent mixing of samples	<ul style="list-style-type: none"> <li>• Be sure all samples and reagents are mixed thoroughly.</li> <li>• When adding reaction mix to each well, place tips at the bottom of the well (beneath the mineral oil) and slowly pipette up and down 3-4 times.</li> <li>• Verify all liquid is expelled from the pipette tip during additions.</li> <li>• Verify the correct sample was added to each well.</li> <li>• Verify the correct sample volume was added to each well.</li> <li>• Verify the calibration information on equipment is current.</li> <li>• Visually inspect plate for consistent volumes between wells.</li> </ul>
	Inconsistent addition of reaction mix	
	Inconsistent addition of sample	
	Suspected contamination during sample addition.	Use nuclease-free aerosol barrier tips and sterile tubes during set up.
		Wear gloves when setting up the test.
		Make sure that pipette tips touch only the solution being dispensed.
		Do not touch pipette tips with hands.

		Clean lab surfaces using appropriate materials.
	Sample evaporation	Verify mineral oil addition to each well.
	Bubbles in the reaction wells	If possible, spin down plates prior to fluorescence scanning.
	Prepared reaction mixes were not used within recommended time period.	Use reaction mixes within 30 minutes of preparation.
Sample displays "IND: Low gDNA" result.	Insufficient number of cells in specimen.	<ul style="list-style-type: none"> <li>• Mix the specimen and repeat DNA extraction.</li> <li>• Verify the correct sample volume was added to each well.</li> <li>• Verify that proper procedure was followed for DNA extraction.</li> </ul>
	Suspected error during DNA extraction.	
	Insufficient amount of DNA was used in the assay.	
	DNA sample inhibition	Repeat DNA extraction from the specimen.
		Refer to Instructions for Use, Performance Characteristics (Interfering Substances) section.
	The DNA sample(s) may not have been completely denatured.	Verify that the sample was denatured at the correct temperature and for an appropriate amount of time.
Sample displays "IND: Low HPV FOZ" result.	Suspected error during DNA extraction	<ul style="list-style-type: none"> <li>• Repeat DNA extraction from the specimen.</li> <li>• Verify that proper procedure was followed for DNA extraction.</li> <li>• Refer to Instructions for Use, Performance Characteristics (Interfering Substances) section.</li> </ul>
	DNA sample inhibition	
Insufficient Sample DNA volume.	Insufficient elution volume during DNA Extraction	Repeat DNA extraction from the specimen.
		Verify that proper procedure was followed for DNA extraction.
High number of DNA samples with positive FAM FOZ values in all three reaction mixes.	Suspected error during DNA extraction	<ul style="list-style-type: none"> <li>• Repeat DNA extraction from the specimen.</li> <li>• Verify that proper procedure was followed for DNA extraction.</li> </ul>
	Suspected DNA extraction reagent contamination	

## TROUBLESHOOTING FOR CERVISTA<sup>®</sup> MTA SYSTEM

Refer to the Troubleshooting section of the Cervista<sup>®</sup> MTA Operator's Manual (Part Number: MAN-02378-002) for Cervista<sup>®</sup> MTA systems.

### Contact Information:



#### Manufacturer:


Hologic, Inc.,  
502 S. Rosa Road,  
Madison, WI, 53719 USA.  
Phone: 608.273.8933  
Website: [www.hologic.com](http://www.hologic.com)

#### Technical Support:

Access routes for Technical Support outside of the US will be advised by your local representative.

#### Distributors:

Contact Hologic for a list of worldwide suppliers and distributors.  
Phone: 608.273.8933  
Website: [www.hologic.com](http://www.hologic.com)



#### Authorized Representative for the European Community:

Hologic UK Ltd.  
Link 10, Napier Way  
Crawley, West Sussex  
RH10 9RA  
+44 (0) 1293 522 080

## NOTICE TO RECIPIENT ABOUT LIMITED LICENSE

The receipt of Product from Hologic, or its authorized distributor, includes a limited, non-exclusive, non-transferable license under certain intellectual property rights held by Hologic. This license is only for the purpose of using the Product in the methods for which they were intended. This limited license does not include a license to use the Product for new product research or development, product manufacture, reverse-engineering, improvements to the Product technology or any other commercial purpose. Customer is not authorized to transfer this Product to any third party for any purpose whatsoever without the express written consent of Hologic. Except as otherwise stated in this paragraph, no other license is granted expressly, impliedly or by estoppel.

For information concerning the availability of additional licenses to practice the patented methodologies, contact:

Legal Department, Hologic, Inc., 502 South Rosa Rd., Madison, WI, 53719, (608) 273-8933.

The Cervista<sup>®</sup> HPV HR test uses a proprietary Invader<sup>®</sup> chemistry and specific components covered under: U.S. Patent Nos. 5,614,402; 5,795,763; 5,846,717; 5,985,557; 5,994,069; 6,001,567; 6,090,543; 6,090,606; 6,348,314; 6,458,535; 6,555,357; 6,562,611; 6,635,463; 6,673,616; 6,759,226; 6,872,816; 6,875,572; 6,913,881; 7,060,436; 7,067,643; 7,087,381; Canadian Patent Nos. 2,163,015; 2,203,627; Australian Patent Nos. 694,736; 731,062; 737,449; 738,849; 744,369; 779,443; 781,188; Japanese Patent No. 3,665,648; European Patent No. 711,361. All U.S. patents and foreign patents where applicable that have or may hereafter issue in respect of such applications for patents; and all U.S. and foreign patent applications and

patents issuing thereon where applicable whose subject matter in whole or in part is entitled to the benefit of the filing date(s) of any of the foregoing patents/patent applications listed in this product insert.

## **LIMITED PRODUCT WARRANTY**

**WARRANTIES.** Equipment, Supplies, and Software are warranted to the original Customer to perform substantially in accordance with published Product Specifications for one (1) year starting from the date of Installation (if applicable) or from the date of Delivery, whichever occurs first. After-sale options and accessories are warranted for six (6) months, and x-ray tubes are warranted on a straight-line prorated basis as stated in the applicable Product Specification ("Warranty Period"). Replacement parts are warranted for the remainder of the Warranty Period or ninety (90) days from Delivery, whichever is longer. Consumable Supplies are warranted to conform to published specifications for a period ending on the expiration date shown on their respective packages. Services are warranted to be supplied in a workman-like manner. Hologic does not warrant that use of Products will be uninterrupted or error-free, or that Products will operate with non-Hologic authorized third-party products. HOLOGIC'S ENTIRE WARRANTY RESPONSIBILITY IS EXPRESSLY LIMITED TO REPAIR OR REPLACEMENT (AT HOLOGIC'S OPTION AND IN THE FORM ORIGINALLY SHIPPED) OF PRODUCT OR CORRECTION OF SERVICE SUBJECT TO ANY CLAIM, OR, AT HOLOGIC'S ELECTION, REPAYMENT OF, OR CREDITING CUSTOMER WITH, AN AMOUNT EQUAL TO THE HOLOGIC PRICE, FEE OR CHARGE THEREFORE. THE FOREGOING WARRANTIES ARE IN LIEU OF AND EXCLUDE ALL OTHER WARRANTIES NOT EXPRESSLY SET FORTH HEREIN, WHETHER EXPRESS OR IMPLIED BY OPERATION OF LAW OR OTHERWISE, INCLUDING BUT NOT LIMITED TO ANY IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. SUCH LIMITED WARRANTY IS GIVEN SOLELY TO THE ORIGINAL CUSTOMER AND IS NOT GIVEN TO, NOR MAY IT BE RELIED UPON BY, ANY THIRD PARTY INCLUDING, WITHOUT LIMITATION, CUSTOMERS OF CUSTOMER. THIS WARRANTY IS VOID UPON TRANSFER OF PRODUCT BY CUSTOMER TO ANY ENTITY WHO HAS LESS THAN FIFTY (50) PERCENT OWNERSHIP IN THE PRODUCT. SOME STATES DO NOT ALLOW THE EXCLUSION OF IMPLIED WARRANTIES SO THE ABOVE EXCLUSIONS MAY NOT APPLY TO YOU. YOU MAY ALSO HAVE OTHER RIGHTS, WHICH VARY, FROM STATE TO STATE. These warranties do not apply to any item that is: (a) repaired, moved or altered other than by Hologic authorized service personnel; (b) subjected to physical (including thermal or electrical) abuse, stress, or misuse; (c) stored, maintained or operated in any manner inconsistent with applicable Hologic specifications or instructions; or (d) designated as supplied subject to a non-Hologic warranty or on a pre-release or "as-is" basis.

**WARRANTY CLAIMS AND REMEDIES.** In the event of any warranty claim, Hologic will replace with new or repaired items any Equipment part, component, or consumable supply that is in breach of warranty, and will use reasonable efforts to promptly fix or provide a workaround for any Software defect or bug which prevents operation in substantial conformity with functional specifications. Alternatively, Hologic may elect to repay or credit to Customer an amount equal to the purchase price of the defective Equipment, component, Software, consumable supply, or Service. Items replaced shall become Hologic property. All claims shall be initiated by contacting Hologic within the applicable warranty period and thirty (30) days after discovery of the breach or non-conformity. Hologic must be given reasonable access and an opportunity to inspect all associated materials. If Hologic and Customer are unable to settle any claim and Customer has not notified Hologic within one (1) year after the claim arises, Customer shall be barred from instituting any legal action thereafter. These remedies shall comprise Hologic's entire liability and Customer's exclusive remedy for breach of warranty and are in lieu of any other remedies at law or equity.

**LIMIT OF LIABILITY.** HOLOGIC SHALL NOT BE LIABLE FOR ANY SPECIAL, INCIDENTAL, PUNITIVE, EXEMPLARY OR CONSEQUENTIAL LOSSES, DAMAGES, OR EXPENSES (INCLUDING BUT NOT LIMITED TO LOSS OF PROFITS, DATA, OR USE), DIRECTLY OR INDIRECTLY ARISING FROM THE SALE, HANDLING, SERVICE OR USE OF PRODUCT ORDERED OR FURNISHED, OR FROM ANY CAUSE RELATING THERETO UNLESS EXPRESSLY AGREED TO BY THE PARTIES IN WRITING.



EXCEPT FOR PERSONAL INJURY OR DEATH TO THE EXTENT RESULTING FROM HOLOGIC'S NEGLIGENCE OR INTENTIONALLY WRONGFUL ACTS OR OMISSIONS, IN NO EVENT SHALL HOLOGIC BE LIABLE UNDER ANY LEGAL THEORY OR FOR ANY CAUSE WHATSOEVER, WHETHER BASED UPON WARRANTY, CONTRACT, TORT, NEGLIGENCE, OR OTHER THEORY, EVEN IF ADVISED OF THE POSSIBILITY THEREOF, FOR ANY AMOUNT IN EXCESS OF THE PRICE, FEE OR CHARGE THEREFORE RECEIVED BY HOLOGIC.

Hologic®, Cervista®, Cleavase®, Invader®, Invader Call Reporter®, PreservCyt®, and ThinPrep® are registered trademarks of Hologic Inc. All other Trademarks / Registered Trademarks referenced within this product insert, are the property of each of their respective companies.

Some components of nucleic acid analysis, such as specific methods and compositions for manipulating or visualizing nucleic acids for analysis, may be covered by one or more patents owned by other parties. Similarly, nucleic acids containing specific nucleotide sequences may be patented. Making, using or selling such components or nucleic acids may require one or more licenses. Nothing in this document should be construed as an authorization or implicit license to make, use or sell any so covered component or nucleic acid under any such patents.

©2011 Hologic, Inc.

Part Number 15-3053, Revision 103

**HOLOGIC®**